AMSA：一项针对难治性和复发性急性髓性白血病的II期试验。
AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia.
作者信息
Boccia R, Zighelboim J, Champlin R E, Kim C C, Gale R P
出版信息
Med Pediatr Oncol. 1984;12(3):178-9. doi: 10.1002/mpo.2950120307.
PMID:6587178
Abstract
27 patients with resistant acute myelogenous leukemia (AML) were treated with AMSA. Three achieved a complete remission, and two a partial remission. Median survival for all patients was 12 weeks and was 16 weeks for responders.
摘要
27例难治性急性髓细胞白血病（AML）患者接受了安吖啶治疗。3例患者实现完全缓解，2例部分缓解。所有患者的中位生存期为12周，缓解者的中位生存期为16周。
Zotero 插件